CDT
CDT Equity Inc.1.7100
-0.0500-2.84%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
2.79MP/E (TTM)
-Basic EPS (TTM)
-179.34Dividend Yield
0%Recent Filings
8-K
10-Q
Q3 FY2025 results
CDT Equity posted Q3 operating loss of $7.0M, up 21% y/y from $5.8M (derived), driven by G&A doubling to $5.5M on stock comp and legal fees while R&D eased 50% to $1.5M post-AstraZeneca license. Nine-month net loss hit $17.9M versus $15.4M y/y, with EPS at $(74.92) on 239K diluted shares reflecting reverse splits. Cash climbed to $3.8M after $18M ATM raises, funding $10.9M op cash burn; $1.7M fair-value A.G.P. note remains. Bitcoin holdings sit at $1.0M. Nasdaq compliance holds—for now.
8-K
1-for-8 reverse stock split
CDT Equity Inc. filed for a 1-for-8 reverse stock split on October 8, 2025, effective October 10 at 5:00 p.m. ET, slashing outstanding shares to about 1.35 million. Trading resumes adjusted on Nasdaq under CDT on October 13. The board aims to boost fundraising for strategy execution. Yet fractional shares get cashed out—no leftovers.
8-K
Financial restatement announced
CDT Equity Inc. announced on August 8, 2025, that its unaudited financial statements for the quarter ended March 31, 2025, can no longer be relied upon due to misclassification of $0.4 million in milestone payments to Sarborg Limited. These payments, tied to a Services Agreement for acquiring a diagnostic tool to monitor clinical trials and track IP, were wrongly expensed as R&D instead of capitalized as an asset under ASC 730. The company will restate via an amended 10-Q. This adjustment bolsters balance sheet accuracy but underscores accounting oversight gaps.
10-Q
Q2 FY2025 results
CDT Equity swung to a deeper Q2 operating loss of $5.0M, up 58% y/y from $3.1M, driven by R&D ramp-up to $1.9M from $25K amid AI partnerships and asset licensing, while G&A held steady at $3.1M. Net loss widened to $6.0M or $5.46/share on 1.1M shares, versus $5.4M or $109.33/share on 49K shares last year, with the delta mainly from fair-value swings on convertible notes outweighing debt gains. Cash climbed to $3.3M on $11.9M ATM equity raises, funding $6.5M operating burn and $0.4M capex; free cash flow not disclosed in the 10-Q. Debt cleared to $1.9M fair value on the remaining A.G.P. note due November 2025. Pipeline advances via AstraZeneca licenses and Sarborg AI tools show promise. Yet Nasdaq compliance hangs by a thread.
IPO
Employees
Sector
Industry
ACET
Adicet Bio, Inc.
0.47-0.03
CELZ
Creative Medical Technology Hol
2.09-0.03
CLDX
Celldex Therapeutics, Inc.
26.68-0.41
CLYM
Climb Bio, Inc.
4.62+0.81
CUBT
CURATIVE BIOTECHNOLOGY INC.
0.01+0.00
CYDY
CytoDyn Inc.
0.32+0.02
EQ
Equillium, Inc.
1.21-0.01
GDTC
CytoMed Therapeutics Limited
1.62+0.02
IMA
ImageneBio, Inc.
6.25+0.08
SABS
SAB Biotherapeutics, Inc.
3.99-0.01